FDA advisers backed approval of Moderna's flu vaccine for adults aged 50 and older, concluding that benefits outweigh the risks. The decision is a positive regulatory step that could support commercialization, though it is not yet the final FDA approval.
FDA advisers backed approval of Moderna's flu vaccine for adults aged 50 and older, concluding that benefits outweigh the risks. The decision is a positive regulatory step that could support commercialization, though it is not yet the final FDA approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
